Key result
Primary prevention statins show clear CVD benefit through age 75, pending trials beyond age 75.
Why the study?
Evidence for primary prevention statin treatment beyond age 75 remains uncertain, and current clinical guidelines conflict regarding recommendations in older adults.
Does primary prevention statin therapy prevent morbidity and mortality from cardiovascular disease in older adults?
Does primary prevention statin therapy prevent morbidity and mortality from cardiovascular disease in older adults?
Primary prevention statin therapy provides clear cardiovascular benefits in adults up to age 75, while ongoing trials will clarify its utility in older populations.
Answers are grounded in this paper and cite their sources.
Supports statin use for primary prevention through age 75; leaves open net benefit beyond age 75 pending ongoing trials.
PURPOSE OF REVIEW: The purpose of this review is to assess the evidence for primary prevention statin treatment in older adults, within the context of the most recent guideline recommendations, while also highlighting important considerations for shared decision-making. RECENT FINDINGS: As the average lifespan increases and the older adult population grows, the opportunity for prevention of morbidity and mortality from cardiovascular disease is magnified. Randomized trials and meta-analyses have demonstrated a clear benefit for primary prevention statin use through age 75, with uncertainty beyond that age. Despite these data supporting their use, current guidelines conflict in their statin treatment recommendations in those aged 70-75 years. Reflecting the paucity of evidence, the same guidelines are equivocal around primary prevention statins in those beyond age 75. Two large ongoing randomized trials (STAREE and PREVENTABLE) will provide additional insights into the treatment benefits and risks of primary prevention statins in the older adult population. In the meantime, a holistic approach in treatment decisions remains paramount for older patients. SUMMARY: The benefits of primary prevention statin treatment are apparent through age 75, which is reflected in the current ACC/AHA and USPSTF recommendations. Ongoing trials will clarify the utility in those beyond age 75.
No takes yet. Share an insight, caveat, or question.
Nanna et al. (2022) conducted a review in Cardiovascular disease. Statin therapy was evaluated. Primary prevention statin treatment demonstrates clear benefit for cardiovascular disease prevention through age 75, with ongoing trials needed to clarify utility in adults beyond age 75.
Synapse has enriched 10 related papers. Consider them for comparative context: